» Articles » PMID: 10929927

Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?

Overview
Journal Drugs
Specialty Pharmacology
Date 2000 Aug 10
PMID 10929927
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Novel biochemical findings on the molecular mechanisms of estrogen actions may help us to understand some of the unexplained observations seen in breast cancer treatment and suggest new therapeutic opportunities. Thus, apart from the challenge of improving the clinical treatment of patients with advanced disease, results from trials in this setting may reveal new therapeutic principles that may be evaluated in the adjuvant setting. The role of endocrine therapy in metastatic as well as early breast cancer is increasing, and the possibility of improving cure rates for breast cancer by implementing therapy with novel aromatase inhibitors in the adjuvant setting is exciting. While the results from prevention trials are most interesting, suggesting the possibility of reducing breast cancer incidence in high-risk groups, more data are needed before we can decide whether such interventions are warranted in women at high risk of developing breast cancer.

Citing Articles

Exemestane: a review of its use in postmenopausal women with breast cancer.

Deeks E, Scott L Drugs. 2009; 69(7):889-918.

PMID: 19441873 DOI: 10.2165/00003495-200969070-00007.

References
1.
Kaufmann M, Bajetta E, Dirix L, Fein L, Jones S, Zilembo N . Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000; 18(7):1399-411. DOI: 10.1200/JCO.2000.18.7.1399. View

2.
Howell A, Barnes D, Harland R, Redford J, Bramwell V, Wilkinson M . Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984; 1(8377):588-91. DOI: 10.1016/s0140-6736(84)90995-4. View

3.
Lundgren S . Progestins in breast cancer treatment. A review. Acta Oncol. 1992; 31(7):709-22. DOI: 10.3109/02841869209083859. View

4.
Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

5.
Lu Q, Liu Y, Long B, Grigoryev D, GIMBEL M, Brodie A . The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat. 1999; 57(2):183-92. DOI: 10.1023/a:1006225601046. View